Costs and cost-effectiveness of Remifentanil Versus Fentanyl for analgo-sedation in Mechanically Ventilated Adult ICU Patients
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
It is common for intubated patients in intensive care units (ICU) to receive the opioids and sedatives infusions to relieve the pain and anxiety associated with invasive mechanical ventilation (IMV). A recent study demonstrated the feasibility of remifentanil. However, there is a notable lack of economic evaluations comparing these agents. This systematic review aimed to address this evidence gap.
Methods
In this systematic review, we searched Ovid MEDLINE, Ovid Embase, and the Cochrane Library for articles published between 1997 and 2023. We included full-text original English articles that reported on economic evaluation. We assessed the study quality using the 24-item Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist.
Results
The search identified 169 abstracts; after removing duplicates, 103 were screened, and 8 full-text articles were assessed. Only two single-centre studies (n=285) met inclusion criteria as economic evaluations. The two studies varied significantly in methodology, including outcomes measured, cost components, time horizons, and perspectives. CHEERS checklist assessed the study qualities to be good (59%; Muellejans’) and very good (81%; Al’s). Although both studies demonstrated reduced IMV duration and ICU length of stay, the economic evaluation revealed conflicting results. While Al’s study found remifentanil may reduce costs, Muellejans’ study found similar total costs mainly due to higher drug prices of remifentanil.
Conclusion
This systematic review found only two heterogeneous studies on remifentanil’s economic impact in ICU, with inconsistent findings. The lack of robust evidence highlights the need for high-quality economic evaluations, given ICU care’s significant costs.
PROSPERO
CRD42022357343
